Business
Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nXeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it began dosing patients in a Phase 2 clinical study to evaluate its investigational ready-to-use, fixed-ratio co-formulation of pramlintide and insulin in patients with diabetes.\n\n\nCurrently, pramlintide and insulin must be administered as two injections at separate sites before every meal, complicating the maintenance process for patients. The Company’s XeriSol™ technology allows for simultaneous concentration and stabilization of insulin and pramlintide, which are incompatible in aqueous (water-based) formulations. Xeris is leveraging its unique capability to develop a new fixed-ratio, co-formulation of pramlintide and insulin in a single injection to potentially improve glycemic control after meals in people with diabetes. In addition to the effects of insulin, pramlintide enhances glucose control by slowing the absorption of carbohydrates in the body and serves to complement the body’s interaction with insulin to regulate blood sugar levels.\n\n\n“The premise of our technology is to simplify and improve therapies that patients rely on every day. With this liquid co-formulation, we have the opportunity to fully unlock the potential of pramlintide in helping persons with diabetes manage their blood sugar levels with a simple combination of commonly used therapies,” said Steven Prestrelski, Chief Scientific Officer of Xeris Pharmaceuticals. “The initiation of this Phase 2 study is our latest step to advance meaningful innovation in the diabetes community and continues the momentum we have built on the heels of our first commercial approval.”\n\n\nThe randomized, open-label, cross-over study will assess the investigational treatment in a group of 18 adults with Type 1 diabetes. The primary objective of the study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) properties of a single injection of pramlintide-insulin compared to single doses of regular insulin and regular insulin plus pramlintide (co-administered as separate injections).\n\n\nThe Company anticipates reporting data from this study in the first half of 2020. For more information on Xeris...